Shepherd J, Packard C J, Patsch J R, Gotto A M, Taunton O D
J Clin Invest. 1979 May;63(5):858-67. doi: 10.1172/JCI109385.
This report describes the effects of pharmacologic doses (3 g/d) of nicotinic acid on the plasma distribution and chemical composition of the high density lipoprotein (HDL) subfractions HDL(2) and HDL(3) and examines the influence of the drug on the metabolism of the major HDL apoproteins, apolipoproteins A-I (ApoA-I) and A-II (Apo-II). The drug lowered plasma cholesterol (15%, P < 0.05) and triglyceride (27%, P < 0.01); the former effect a result of a fall in the amount of cholesterol associated with very low density lipoproteins (31%, P < 0.02) and low density lipoproteins (36%, P < 0.02). Conversely, it raised plasma HDL cholesterol (23%, P < 0.05) and increased (by 345%) the plasma HDL(2):HDL(3) ratio. The latter derived from an absolute increment (646%) in circulating HDL(2), coupled with a fall (47%) in HDL(3). This change was not associated with major alterations in the overall cholesterol (free and esterified), triglyceride, phospholipid, or protein content of the subfractions; however, it was accompanied by substantial changes in their protein composition. In particular, the molar ratio of ApoA-I:ApoA-II in HDL(3) declined from 2.7:1 to 2.1:1 during nicotinic acid treatment.Significant perturbations of ApoA-I and ApoA-II metabolism accompanied the drug-induced HDL subfraction redistribution. Specifically, the plasma concentration of ApoA-I rose by 7% (P < 0.05) because of a decrease in its fractional catabolic rate. Moreover, whereas before treatment 6 and 94% of the plasma ApoA-I circulated with HDL(2) and HDL(3), after commencement of nicotinic acid therapy this distribution became 49 and 51% in HDL(2) and HDL(3), respectively. ApoA-II was found mainly in HDL(3), both before and during nicotinic acid treatment. Administration of the drug caused a 14% reduction in its plasma concentration (P < 0.05), which derived principally from a fall (22%, P < 0.01) in its synthetic rate. These data suggest that the effects of nicotinic acid on the HDL subfraction distribution may be mediated via (a) net transfer of ApoA-I from HDL(3) to HDL(2) and (b) a reduction in ApoA-II synthesis. Our present understanding of the association between HDL and atherosclerosis indicates that such changes may have prophylactic value in the prevention of coronary artery disease.
本报告描述了药理剂量(3克/天)的烟酸对高密度脂蛋白(HDL)亚组分HDL(2)和HDL(3)的血浆分布及化学组成的影响,并研究了该药物对主要HDL载脂蛋白——载脂蛋白A-I(ApoA-I)和A-II(Apo-II)代谢的影响。该药物可降低血浆胆固醇(15%,P<0.05)和甘油三酯(27%,P<0.01);前一效应是由于与极低密度脂蛋白相关的胆固醇量下降(31%,P<0.02)以及低密度脂蛋白下降(36%,P<0.02)所致。相反,它可提高血浆HDL胆固醇(23%,P<0.05)并增加(345%)血浆HDL(2):HDL(3)比值。后者源于循环中HDL(2)的绝对增加(646%),同时HDL(3)下降(47%)。这种变化与亚组分的总胆固醇(游离和酯化)、甘油三酯、磷脂或蛋白质含量的主要改变无关;然而,其蛋白质组成发生了显著变化。特别是,在烟酸治疗期间,HDL(3)中ApoA-I:ApoA-II的摩尔比从2.7:1降至2.1:1。药物诱导的HDL亚组分重新分布伴随着ApoA-I和ApoA-II代谢的显著扰动。具体而言,ApoA-I的血浆浓度上升了7%(P<0.05),这是由于其分数分解代谢率降低所致。此外,治疗前血浆中6%和94%的ApoA-I分别与HDL(2)和HDL(3)一起循环,烟酸治疗开始后,HDL(2)和HDL(3)中的这种分布分别变为49%和51%。在烟酸治疗前和治疗期间,ApoA-II主要存在于HDL(3)中。给药导致其血浆浓度降低14%(P<0.05),这主要源于其合成率下降(22%,P<0.01)。这些数据表明,烟酸对HDL亚组分分布的影响可能通过(a)ApoA-I从HDL(3)向HDL(2)的净转移以及(b)ApoA-II合成的减少来介导。我们目前对HDL与动脉粥样硬化之间关联的理解表明,此类变化在预防冠状动脉疾病方面可能具有预防价值。